UK Recombinant Protein Therapeutics Cdmo Market Size & Outlook
UK recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
UK recombinant protein therapeutics cdmo market highlights
- The UK recombinant protein therapeutics cdmo market generated a revenue of USD 1,213.4 million in 2023 and is expected to reach USD 3,028.4 million by 2030.
- The UK market is expected to grow at a CAGR of 14% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 1,213.4 million |
| Market revenue in 2030 | USD 3,028.4 million |
| Growth rate | 14% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, UK accounted for 5.8% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 2,892.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.49% in 2023. Horizon Databook has segmented the UK recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
The market in the UK is lucrative owing to the implementation of tax credits and various expansion strategies. For instance, in March 2023, The MHRA stated that it would take certain initiatives to streamline the clinical trials in the country by making the approval procedure and capability to run clinical studies in the country easy. This is expected to improve clinical research in the country over time and promote the market in the UK.
Moreover, market growth can be attributed to various factors, such as the presence of various multinational CDMOs, significant R&D spending, growing healthcare research, and rapidly evolving therapeutic approaches. For example, in March 2022, the UK government announced that over USD 347 million would be allocated for healthcare research to improve research activities in the region.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
UK Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
